KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Revenue: 2009-2024

Historic Revenue for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $1.0 billion.

  • Halozyme Therapeutics' Revenue rose 22.12% to $354.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 31.19%. This contributed to the annual value of $1.0 billion for FY2024, which is 22.44% up from last year.
  • As of FY2024, Halozyme Therapeutics' Revenue stood at $1.0 billion, which was up 22.44% from $829.3 million recorded in FY2023.
  • Halozyme Therapeutics' 5-year Revenue high stood at $1.0 billion for FY2024, and its period low was $267.6 million during FY2020.
  • For the 3-year period, Halozyme Therapeutics' Revenue averaged around $834.9 million, with its median value being $829.3 million (2023).
  • Data for Halozyme Therapeutics' Revenue shows a peak YoY soared of 65.67% (in 2021) over the last 5 years.
  • Over the past 5 years, Halozyme Therapeutics' Revenue (Yearly) stood at $267.6 million in 2020, then soared by 65.67% to $443.3 million in 2021, then spiked by 48.91% to $660.1 million in 2022, then grew by 25.62% to $829.3 million in 2023, then climbed by 22.44% to $1.0 billion in 2024.